AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,511 AI briefs of material SEC Form 8-K filings by 4,787 companies: 2,125 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,511every one kept
Companies4,787with at least one brief
Recent filings2,125filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
United States Antimony Corporation announced that it will release its third quarter 2026 financial and operating results and hold a conference call and webcast on Thursday, November 12, 2026, at 4:15 p.m. Eastern time. The filing only sets the date and time and does not include any results, so it gives shareholders no new financial figures.
- Third quarter 2026 results and nine-month results to be released after U.S. markets close on November 12, 2026
- Conference call and webcast begin at 4:15 p.m. Eastern time on November 12, 2026
- Press release announcing the date was issued November 9, 2026 and filed as Exhibit 99.1
Read the filing on SEC.gov ↗
Cincinnati Financial posted investor presentation slides on November 9, 2026 for use from November 10, 2026. The slides show third-quarter 2026 EPS of $2.96 versus $7.11 in 3Q25, while non-GAAP operating income was $443 million compared with $449 million, and the combined ratio rose to 90.9%. The company said its year-to-date value creation ratio of 5.8% was below its 10% to 13% long-term target.
- 3Q26 EPS of $2.96 per share versus $7.11 per share in 3Q25
- Non-GAAP operating income of $443 million versus $449 million in 3Q25
- Combined ratio of 90.9%, 2.7 percentage points higher than 3Q25, including 7.0 points from higher catastrophe losses
- YTD 9-30-26 value creation ratio of 5.8%, below the 10% to 13% target; P&C net written premiums grew 4%
Read the filing on SEC.gov ↗
Somnigroup released an updated investor presentation on November 9, 2026, alongside its third-quarter 2026 results. Third-quarter net sales rose 10.8% to $2,351 million, and adjusted EPS rose to $1.04 from $0.95, but GAAP net income fell 7.8% to $164 million and GAAP EPS fell to $0.74 from $0.83. The company's 2026 outlook calls for adjusted EPS of $2.90 at the midpoint and sales of approximately $8.65 billion.
- Q3 2026 net sales were $2,351 million, up from $2,123 million in Q3 2025
- Q3 2026 GAAP EPS was $0.74, down from $0.83; adjusted EPS was $1.04, up from $0.95
- Q3 2026 adjusted EBITDA was $448 million, up from $419 million
- 2026 outlook: adjusted EPS of $2.90 at the midpoint and sales of approximately $8.65 billion
Read the filing on SEC.gov ↗
Marygold Companies reported results for the fiscal first quarter ended September 30, 2026. Revenue rose to $9.4 million from $5.2 million a year earlier, and net income was $1.8 million, or $0.04 per share, compared with a net loss of $0.4 million, or $0.01 per share. The company also disclosed a pending definitive merger agreement under which funds managed by Madison Dearborn Partners would acquire all outstanding shares for $2.00 per share.
- Revenue of $9.4 million for the quarter, up from $5.2 million a year earlier, excluding $1.5 million from discontinued New Zealand operations
- Net income of $1.8 million, or $0.04 per share, versus a net loss of $0.4 million, or $0.01 per share, a year earlier
- USCF Investments average assets under management rose to $5.5 billion from $2.9 billion a year earlier
- Pending merger at $2.00 per share by Madison Dearborn Partners, expected to close in the first half of 2027 or earlier
Read the filing on SEC.gov ↗
KALA BIO reported preliminary, unaudited results for the quarter ended September 30, 2026, showing a net loss of approximately $0.8 million, down from $7.6 million a year earlier. Cash, cash equivalents and short-term investments were approximately $7.0 million with no debt, and the company expects to file its Form 10-Q on or about November 16, 2026. Final results may differ from these preliminary figures, which shareholders should weigh against the pending review.
- Q3 2026 net loss of approximately $0.8 million vs. $7.6 million in Q3 2025
- Nine-month 2026 net loss of approximately $4.0 million vs. $27.7 million in the same period of 2025
- Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt
- Form 10-Q expected on or about November 16, 2026; results remain preliminary and unaudited
Read the filing on SEC.gov ↗
Telos Corporation reported third quarter 2026 revenue of $55.2 million, up from $51.4 million a year earlier, and GAAP net income of $4.4 million, or $0.06 per diluted share, compared with a net loss of $2.1 million a year earlier. The company also raised its full-year 2026 revenue and adjusted EBITDA outlook, which points to stronger results for shareholders.
- Q3 2026 revenue was $55.2 million, versus $51.4 million in Q3 2025.
- GAAP net income was $4.4 million ($0.06 per diluted share), compared with a net loss of $2.1 million ($0.03 per share) a year earlier.
- Full-year 2026 revenue outlook was raised to $198.2 million-$200.7 million from $187 million-$195 million.
- Full-year 2026 adjusted EBITDA outlook was raised to $32.3 million-$34.1 million from $23.6 million-$28.6 million.
Read the filing on SEC.gov ↗
United-Guardian reported higher third-quarter 2026 results, with net sales up 54% to $3,494,780 and net income up 247% to $930,912, or $0.20 per share. For the first nine months, net sales rose 25% to $9,475,269 and net income rose 70% to $2,478,393, or $0.54 per share, showing growth in both periods for shareholders.
- Q3 2026 net sales were $3,494,780, up 54% from $2,264,261 in Q3 2025.
- Q3 2026 net income was $930,912 ($0.20 per share), up 247% from $268,441 ($0.06 per share).
- Nine-month 2026 net sales were $9,475,269, up 25%; net income was $2,478,393 ($0.54 per share), up 70%.
- Pharmaceutical sales grew 29% in the quarter, driven primarily by Renacidin; cosmetic ingredient sales rose 187%.
Read the filing on SEC.gov ↗
Fervo Energy reported third-quarter 2026 results, with net income of $11.7 million driven largely by a $29.9 million tax benefit and an $11.8 million non-cash swap gain, while operating loss widened to $43.7 million from $13.7 million a year earlier. The company lowered its expected second-half 2026 capital spending to $700 million to $750 million from $850 million to $900 million, and said Cape Google 400 commercial operation dates are unchanged, which matters for shareholders weighing construction costs and timing.
- Q3 2026 net income of $11.7 million, versus a net loss of $15.8 million in Q3 2025; the release cites $15.4 million of interest income and two non-recurring items
- Q3 2026 operating loss of $43.7 million; general and administrative expense rose to $39.4 million from $27.4 million in Q2 2026
- Second-half 2026 capital expenditure outlook cut to $700 million to $750 million from $850 million to $900 million, with no change to expected commercial operation dates
- Signed a 15-year take-or-pay power purchase agreement with Google for 396 megawatts, with first power expected mid-2028
Read the filing on SEC.gov ↗
OneMedNet said year-to-date bookings reached approximately $18.76 million as of November 6, 2026, with $1.388 million converted to revenue through September 30, 2026. The company also reported that contracted demand is nearly 14 times its full-year 2025 bookings and that roughly half of its 2026 contracts come from new customers, while providing fourth-quarter 2026 guidance without figures in the filing text.
- Year-to-date bookings: approximately $18.76 million as of November 6, 2026
- Revenue converted from bookings: $1.388 million through September 30, 2026
- Contracted demand is nearly 14 times full-year 2025 bookings
- Roughly half of 2026 contracts are from new customers
Read the filing on SEC.gov ↗
Neurogene Inc. reported third quarter 2026 results, with a net loss of $29.0 million for the three months ended September 30, 2026, up from $21.0 million a year earlier. Higher R&D and G&A spending, driven largely by NGN-401 development and stock-based compensation, drove the increase, and the company said its cash position is expected to fund operations into the first quarter of 2029.
- Net loss was $29.0 million for Q3 2026, compared with $21.0 million for Q3 2025.
- R&D expenses rose to $23.5 million from $17.2 million, mainly for NGN-401 clinical trial and manufacturing activities.
- G&A expenses rose to $8.9 million from $6.6 million, mainly from higher non-cash stock-based compensation.
- Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, expected to fund operations into the first quarter of 2029.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.